Shin Nippon Biomedical Laboratories, Ltd. (YB3.F)

7.95 -0.30 (-3.64%) At close: 08:15AM CEST

Shin Nippon Biomedical Laboratories, Ltd.

2438 Miyanoura-cho
Kagoshima 891-1394
Japan
81 9 9294 3389
https://www.snbl.co.jp

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Ryoichi Nagata F.F.P.M., M.D., Ph.D.	Chairman, CEO, President, Head of Fisheries Business & CHO	865.97k	N/A	1958
Fumihiko Makino	Senior Executive Officer, Financial Controller and GM of Finance & Accounting	N/A	N/A	N/A
Toshiyuki Iwata	Managing Executive Officer and GM of IR Public Relations Department & Sustainability	N/A	N/A	N/A
Shinji Nitanda	Senior MD of Corporate Development & Corporate Tax Administration and Director	N/A	N/A	1968
Kyomi Nagatoshi	Managing Executive Officer, Head of General Affairs & Human Resources and Director	N/A	N/A	N/A
Mr. Ken Takanashi CPA, MBA.	Executive VP of Group Corporate Management & Global Business & Director	N/A	N/A	1964
Satoshi Matsumoto	Managing Executive Officer & GM of Fisheries Division	N/A	N/A	1968
Dr. Hideshi Tsusaki DVM Ph.D.	Senior MD, President of Non-Clinical & Global Business Development and Director	N/A	N/A	1967
Terumasa Hirai	Managing Executive Officer, Preclinical Company VP & Director of Safety Research Institute	N/A	N/A	N/A
Mr. Eishi Tsunozaki	Senior MD & Director	N/A	N/A	1967

Amounts are as of December 31, 2010 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the transactional research and medipolis businesses in Japan and internationally. It offers non-clinical studies, including single/repeated dose toxicity studies, antigenicity studies, skin sensitization studies, genotoxicity studies, carcinogenicity studies, local irritation studies, inhalation toxicity studies, TK studies, characteristic studies, stability studies, dependence studies, reproductive and developmental toxicity studies, safety pharmacological studies, and pharmacokinetic studies. The company also engages in the investigator brochure preparation support, clinical trial protocol creation support, clinical trial medical institution, investigational drug allocation, clinical trial request/contract, monitoring, quality management, data management, statistical analysis work, comprehensive report creation support, electronic application support, regulatory affairs consulting, and creating informed consent documents support services. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of vaccines and therapeutic drugs, antibody drugs, nucleic acid drugs, peptide drugs, gene therapy, and regenerative medicines. Further, the company is involved in the operates geothermal power generation; operates hotel accommodation facilities; and wellbeing businesses, as well as provides cleaning, clerical work, and welfare services. Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.

Corporate Governance

Shin Nippon Biomedical Laboratories, Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.